These results demonstrate that cachexia associated with Fn14 signalling is associated with increased tumour glucose metabolism and that 18F‐FDG positron emission tomography imaging could be used to monitor patient response to anti‐Fn14 antibody 002 cachexia treatments in clinical trials. This evidence concerns the gene TNFRSF12A and Cachexia.